Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
None of the driver gene mutations frequently found in multiple myeloma (MM) such as NRAS, KRAS, BRAF, and TP53 was detected.
|
30635632 |
2019 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These include typical driver mutations in MM such as in KRAS, NRAS, or BRAF.
|
28380360 |
2017 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Paired BM MM cell DNA and ctDNA from 33 relapsed/refractory (RR) and 15 newly diagnosed (ND) patients were analysed for KRAS, NRAS, BRAF and TP53 mutations using the OnTarget Mutation Detection (OMD) platform.
|
27899805 |
2017 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
KRAS and NRAS exon 3 mutations were significantly associated with the myeloma cohort compared with non-myeloma plasma cell dyscrasias (odds ratio (OR) 9.87, 95% confidence interval (CI) 1.07-90.72, P=0.043 and OR 7.03, 95% CI 1.49-33.26, P=0.014).
|
28234344 |
2017 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In total, 98 patients were included in this retrospective translational research study and were evaluated for Kirsten rat sarcoma viral oncogene homolog (KRAS) mutational status, and v-akt murine thymoma viral oncogene homolog 1 (AKT1), AKT serine/threonine kinase 2 (AKT2), AKT serine/threonine kinase 3 (AKT3), cyclin D1 (CCND1), epidermal growth factor receptor (EGFR), mitogen-activated protein kinase 1 (MAPK1), hepatocellular growth factor receptor (MET), avian myelomatosis viral oncogene homolog (MYC), nuclear factor kappa B subunit 1 (NFKb1), phosphatase and tensin homolog (PTEN) and mechanistic target of rapamycin (FRAP1) genes mRNA expression.
|
27919956 |
2016 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Multiple myeloma (MM) was characterized by frequent mutations in KRAS/NRAS/BRAF within the EGFR pathway that could induce resistance to EGFR inhibitors.
|
25894462 |
2015 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We used deep sequencing to screen 167 representative patients with PC dyscrasias [132 with MM, 24 with primary PC leukemia (pPCL) and 11 with secondary PC leukemia (sPCL)] for mutations in BRAF, NRAS and KRAS, which were respectively found in 12%, 23.9% and 29.3% of cases.
|
26090869 |
2015 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These findings identify a significant clinical impact of NRAS mutation in myeloma and demonstrate a clear example of functional differences between the KRAS and NRAS oncogenes.
|
24335104 |
2014 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We observed frequent mutations in KRAS (particularly in previously treated patients), NRAS, BRAF, FAM46C, TP53, and DIS3 (particularly in nonhyperdiploid MM).
|
24434212 |
2014 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here, we report a mutation analysis of N- and K-Ras genes in purified plasma cell populations from a panel of 81 newly diagnosed MM patients stratified according to the most frequent genetic and molecular features associated with the neoplasia.
|
17036375 |
2007 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma.
|
16321859 |
2006 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We found that the growth factor-independent proliferative phenotype in MM cell lines harboring a mutant N- or K-ras gene requires EZH 2 activity.
|
16007202 |
2005 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To address this issue in myeloma, we used the ANBL-6 myeloma cell line where interleukin (IL)-6-dependent cells are stably transfected with mutated N-ras or K-ras genes.
|
12813136 |
2003 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
NRAS and/or KRAS2 mutations were found in 54.5% of MM at diagnosis (but in 81% at the time of relapse), in 50% of P-PCL, and in 50% of 16 HMCL.
|
11524732 |
2001 |
Multiple Myeloma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Multiple Myeloma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|